

---

**Supplementary information**

---

# **Activation of the GLP-1 receptor by a non-peptidic agonist**

---

In the format provided by the  
authors and unedited

Peishen Zhao, Yi-Lynn Liang, Matthew J. Belousoff, Giuseppe Deganutti, Madeleine M. Fletcher, Francis S. Willard, Michael G. Bell, Michael E. Christe, Kyle W. Sloop, Asuka Inoue, Tin T. Truong, Lachlan Clydesdale, Sebastian G. B. Furness, Arthur Christopoulos, Ming-Wei Wang, Laurence J. Miller, Christopher A. Reynolds, Radostin Danev, Patrick M. Sexton & Denise Wootten

**Supplemental Table 1. CryoEM data collection, refinement and model parameters**

|                                                     |                                                        |
|-----------------------------------------------------|--------------------------------------------------------|
|                                                     | <i>TT-OAD2:GLP1R: Gs</i><br>(EMDB-20179)<br>(PDB 6ORV) |
| <b>Data collection and processing</b>               |                                                        |
| Magnification                                       | 105,000 (indicated); 60,530 (actual)                   |
| Voltage (kV)                                        | 300                                                    |
| Electron exposure (e <sup>-</sup> /Å <sup>2</sup> ) | 65.6 and 63.5 (super resolution)                       |
| Defocus range (μm)                                  | 0.7 – 1.5                                              |
| Pixel size (Å)                                      | 0.826                                                  |
| Symmetry imposed                                    | C1                                                     |
| Initial particle images (no.)                       | 1,470,000                                              |
| Final particle images (no.)                         | 85,978                                                 |
| Map resolution (Å)                                  | 3.0                                                    |
| FSC threshold                                       | 0.143                                                  |
| Map resolution range (Å)                            | 200-1.65                                               |
| <b>Refinement</b>                                   |                                                        |
| Initial model used (PDB code)                       | 6B3J                                                   |
| Model resolution (Å)                                | 3.0                                                    |
| FSC threshold                                       | 0.143                                                  |
| Model resolution range (Å)                          | 999-1.65                                               |
| Map sharpening <i>B</i> factor (Å <sup>2</sup> )    | -70                                                    |
| Model composition                                   |                                                        |
| Non-hydrogen atoms                                  | 8041                                                   |
| Protein residues                                    | 997                                                    |
| Ligands                                             | 1                                                      |
| <i>B</i> factors (Å <sup>2</sup> )                  |                                                        |
| Protein                                             | 38                                                     |
| Ligand                                              | 76                                                     |
| R.m.s. deviations                                   |                                                        |
| Bond lengths (Å)                                    | 0.008                                                  |
| Bond angles (°)                                     | 0.857                                                  |
| Validation                                          |                                                        |
| MolProbity score                                    | 1.56                                                   |
| Clashscore                                          | 4.89                                                   |
| Poor rotamers (%)                                   | 0                                                      |
| Ramachandran plot                                   |                                                        |
| Favored (%)                                         | 95.7                                                   |
| Allowed (%)                                         | 4.3                                                    |
| Disallowed (%)                                      | 0                                                      |

**Supplemental Table 2. Effect of GLP-1R mutations on cell surface expression and cAMP signalling.** cAMP data in figure 2 were analysed using a three-parameter logistic equation to derive  $pEC_{50}$  and  $E_{max}$  values.  $pEC_{50}$  values represent the negative logarithm of the concentration of agonist that produces half the maximal response.  $E_{max}$  are presented as a % of the WT response. The same data was analysed using the operational model of agonism to derive functional affinity values ( $\text{Log } K_A$ ) and efficacy values ( $\text{Log } \tau_c$ ) that were corrected to the cell surface expression data as determined by ELISA. These are reported as  $\text{Log } \tau_c$ . All values are expressed as mean  $\pm$  S.E.M. of four individual experiments.

| Construct              | Cell surface<br>Expression (%<br>WT) | $pEC_{50}$      | $E_{max}$ (% WT) | $\text{Log } K_A$ | $\text{Log } \tau_c$ |
|------------------------|--------------------------------------|-----------------|------------------|-------------------|----------------------|
| Wildtype               | -                                    | $6.88 \pm 0.09$ | $100 \pm 2$      | $-6.55 \pm 0.12$  | $0.195 \pm 0.05$     |
| Y145 <sup>1.40</sup> A | $88 \pm 8$                           | $6.09 \pm 0.34$ | $55 \pm 9$       | $-6.01 \pm 0.25$  | $-0.300 \pm 0.16$    |
| Y148 <sup>1.43</sup> A | $67 \pm 8$                           | ND              | ND               | ND                | ND                   |
| K197 <sup>2.67</sup> A | $22 \pm 4$                           | ND              | ND               | ND                | ND                   |
| L201 <sup>2.71</sup> A | $94 \pm 2$                           | $5.73 \pm 0.36$ | $51 \pm 9$       | $-5.55 \pm 0.33$  | $-0.346 \pm 0.16$    |
| W203 <sup>2.73</sup> A | $94 \pm 6$                           | $6.53 \pm 0.27$ | $50 \pm 4$       | $-6.30 \pm 0.31$  | $-0.363 \pm 0.09$    |
| M204 <sup>2.74</sup> A | $99 \pm 2$                           | $5.86 \pm 0.45$ | $42 \pm 11$      | $-5.70 \pm 0.34$  | $-0.488 \pm 0.15$    |
| L217 <sup>ECL1</sup> A | $109 \pm 5$                          | $6.55 \pm 0.34$ | $69 \pm 7$       | $-6.31 \pm 0.46$  | $-0.212 \pm 0.09$    |
| Y220 <sup>ECL1</sup> A | $94 \pm 4$                           | $5.07 \pm 0.82$ | $14 \pm 9$       | ND                | ND                   |
| F230 <sup>3.33</sup> A | $92 \pm 6$                           | $6.26 \pm 0.34$ | $55 \pm 8$       | $-6.03 \pm 0.29$  | $-0.292 \pm 0.11$    |
| M233 <sup>3.36</sup> A | $126 \pm 7$                          | $5.80 \pm 0.30$ | $13 \pm 2$       | $-5.77 \pm 0.53$  | $-1.22 \pm 0.42$     |
| T298 <sup>ECL2</sup> A | $85 \pm 6$                           | $6.65 \pm 0.40$ | $64 \pm 7$       | $-6.41 \pm 0.36$  | $-0.152 \pm 0.13$    |
| W297 <sup>ECL2</sup> A | $60 \pm 7$                           | $5.85 \pm 0.21$ | $44 \pm 5$       | $-5.69 \pm 0.40$  | $-0.314 \pm 0.17$    |

**Supplemental Table 3. GLP-1R systems prepared and simulated in the present work.**

Besides the GLP-1R:Gs protein complexes bound to TT-OAD2 (GLP-1R:TT-OAD2:Gs) and GLP-1 (GLP-1R:GLP-1:Gs), the two corresponding complex without Gs protein (GLP-1R:TT-OAD2 and GLP-1R:GLP-1, respectively) and the two apo receptors (apo-GLP-1R (TT-OAD2) and apo-GLP-1R (GLP-1), respectively) were prepared as described above and subject to four MD replicas each.

| GLP-1R System        | Number of replicas | Total MD simulation time |
|----------------------|--------------------|--------------------------|
| GLP-1R:TT-OAD2:Gs    | 4                  | 2 $\mu$ s                |
| GLP-1R:TT-OAD2       | 4                  | 4 $\mu$ s                |
| Apo-GLP-1R (TT-OAD2) | 4                  | 4 $\mu$ s                |
| GLP-1R:GLP-1:Gs      | 4                  | 2 $\mu$ s                |
| GLP-1R:GLP-1         | 4                  | 4 $\mu$ s                |
| Apo-GLP-1R (GLP-1)   | 4                  | 4 $\mu$ s                |